Home › Funds › CAXTON CORP › ALXO
CAXTON CORP position in ALXO
ALX ONCOLOGY HLDGS INC · Health Care
CAXTON CORP reported holding 20,946 shares of ALXO (ALX ONCOLOGY HLDGS INC) in its Q2 2026 13F filing — a position valued at US$43K, representing 2.34% of its reported portfolio and ranking #10 among its reported holdings. CAXTON CORP has disclosed ALXO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How CAXTON CORP's ALXO position evolved
CAXTON CORP first disclosed a stake in ALXO in Q1 2026 at 20,946 shares (US$42K). The position peaked in Q2 2026 at 20,946 shares, worth US$43K. Across 2 filings, CAXTON CORP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 20,946 shares valued at US$43K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 20.95K | $42.00K | New |
| Q2 2026 | 20.95K | $43.36K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALXO and 13F data
ALXO (ALX ONCOLOGY HLDGS INC) is a Health Care company. 36 other funds we track also report a position in ALXO — the largest reported positions include venBio Partners LLC (US$26.7M), Redmile Group, LLC (US$15.3M), SILVERARC CAPITAL MANAGEMENT, LLC (US$11.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALXO
- venBio Partners LLC 12.88M sh · $26.67M · Q2 2026
- Redmile Group, LLC 7.39M sh · $15.30M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 5.74M sh · $11.89M · Q2 2026
- TCG Crossover Management, LLC 5.66M sh · $11.71M · Q2 2026
- Vivo Capital, LLC 3.18M sh · $6.59M · Q2 2026
- 5AM Venture Management, LLC 3.06M sh · $6.33M · Q2 2026
- Almitas Capital LLC 2.94M sh · $6.08M · Q2 2026
FAQ
How long has CAXTON CORP held ALXO?
CAXTON CORP has disclosed ALXO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is CAXTON CORP's current position in ALXO?
As of Q2 2026, CAXTON CORP holds 20.95K shares of ALXO (ALX ONCOLOGY HLDGS INC), valued at $43.36K, representing 2.34% of its reported portfolio and ranking #10.
Has CAXTON CORP been buying or selling ALXO?
In the latest 13F filing (Q2 2026), CAXTON CORP held unchanged its position in ALXO. The position peaked in Q2 2026 at 20.95K shares.
Which other funds hold ALXO?
Other major institutional holders of ALXO include venBio Partners LLC, Redmile Group, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.